MAIA BIOTECHNOLOGY INC (MAIA) Stock Price, Forecast & Analysis
USA - NYSEARCA:MAIA - US5526411021 - Common Stock
MAIA Key Statistics, Chart & Performance
The current stock price of MAIA is 1.01 USD. In the past month the price decreased by -24.24%. In the past year, price decreased by -51.92%.
MAIA Latest News, Press Relases and Analysis
MAIA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.8 | 414.01B | ||
| AMGN | AMGEN INC | 15.73 | 185.25B | ||
| GILD | GILEAD SCIENCES INC | 15.39 | 156.42B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.01 | 111.34B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.04 | 76.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 914.29 | 61.12B | ||
| INSM | INSMED INC | N/A | 42.84B | ||
| NTRA | NATERA INC | N/A | 29.42B | ||
| BIIB | BIOGEN INC | 10.07 | 24.72B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.07 | 21.56B | ||
| INCY | INCYTE CORP | 16.31 | 20.45B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.28 | 13.80B |
Related stock screener links
About MAIA
Company Profile
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2022-07-28. The firm's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
Company Info
MAIA BIOTECHNOLOGY INC
444 West Lake Street, Suite 1700, Suite 1700
Chicago ILLINOIS US
Employees: 13
Phone: 13124168592
MAIA BIOTECHNOLOGY INC / MAIA FAQ
What does MAIA do?
MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. The company is headquartered in Chicago, Illinois and currently employs 13 full-time employees. The company went IPO on 2022-07-28. The firm's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
Can you provide the latest stock price for MAIA BIOTECHNOLOGY INC?
The current stock price of MAIA is 1.01 USD. The price increased by 1% in the last trading session.
Does MAIA stock pay dividends?
MAIA does not pay a dividend.
What is the ChartMill rating of MAIA BIOTECHNOLOGY INC stock?
MAIA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Who owns MAIA BIOTECHNOLOGY INC?
You can find the ownership structure of MAIA BIOTECHNOLOGY INC (MAIA) on the Ownership tab.
What is the outstanding short interest for MAIA BIOTECHNOLOGY INC?
The outstanding short interest for MAIA BIOTECHNOLOGY INC (MAIA) is 3.86% of its float.
MAIA Technical Analysis
MAIA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MAIA. The financial health of MAIA is average, but there are quite some concerns on its profitability.
MAIA Financial Highlights
Over the last trailing twelve months MAIA reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 46.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.41% | ||
| ROE | -417.16% | ||
| Debt/Equity | 0 |
MAIA Forecast & Estimates
7 analysts have analysed MAIA and the average price target is 12.38 USD. This implies a price increase of 1125.51% is expected in the next year compared to the current price of 1.01.